Daewoong Pharmaceutical's 'Pexuclu Tablet' Wins Grand Prize at Korea New Drug Development Awards

Daewoong Pharmaceutical Headquarters Building Exterior View

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical's domestically produced new drug for gastroesophageal reflux disease treatment, Pexuclu Tablet (active ingredient: Pexuprazan Hydrochloride), has won the Grand Prize in New Drug Development.

Daewoong Pharmaceutical announced on the 21st that it received the Grand Prize in the New Drug Development category at the 23rd Korea New Drug Development Awards (KNDA) for its development of Pexuclu Tablet. The Korea New Drug Development Awards are organized by the Korea New Drug Development Association and sponsored by the Ministry of Health and Welfare, the Ministry of Trade, Industry and Energy, and the Ministry of Science and ICT. The award ceremony will be held on the 23rd at the Samjung Hotel in Gangnam-gu, Seoul.

The New Drug Development Award is selected by the association's review committee after evaluating the novelty, technological level, added value, technological and market competitiveness, and contribution to public health improvement of pharmaceuticals that have obtained product approval within the last three years.

Developed purely with domestic technology since 2008 and approved for marketing last December, Daewoong Pharmaceutical's new drug Pexuclu Tablet is recognized as the top new drug in the gastroesophageal reflux disease treatment category. To date, it has successfully secured technology exports worth approximately 1.1 trillion KRW worldwide, including the United States, China, the Middle East, and Latin America, proving the excellence of the formulation.

Pexuclu Tablet is a P-CAB drug that reversibly blocks proton pumps that secrete gastric acid in the stomach lining, unlike PPI-class treatments. It is evaluated to improve symptoms faster and maintain effects longer than PPI-class drugs. From the initial administration, it immediately alleviated heartburn symptoms regardless of day or night, and also improved chronic cough symptoms, one of the atypical symptoms of gastroesophageal reflux disease. Notably, in patients with severe symptoms, it showed an effect of improving heartburn symptoms in three times more patients compared to the control group treated with Esomeprazole.

Seungho Jeon, CEO of Daewoong Pharmaceutical, said, “We are deeply grateful for the award, which honors the efforts of our company and researchers who have devoted themselves to research and development,” and added, “We will accelerate further research and development and technology exports so that people worldwide can experience relief through Pexuclu Tablet.”

This content was produced with the assistance of AI translation services.